Estrella Immunopharma, Inc.
General ticker "ESLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $42.5M (TTM average)
Estrella Immunopharma, Inc. follows the US Stock Market performance with the rate: 31.1%.
Estimated limits based on current volatility of 4.7%: low 1.15$, high 1.27$
Factors to consider:
- Total employees count: 1 as of 2024
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.63$, 2.22$]
- 2025-12-31 to 2026-12-31 estimated range: [0.48$, 1.76$]
Financial Metrics affecting the ESLA estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.73 <= 0.06
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 0 > -0.64
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ESLA quotes
Long-term ESLA plot with estimates
Financial data
| YTD | 2024-06-30 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $7.31MM | $8.85MM |
| Operating Income | $-7.31MM | $-8.85MM |
| R&D Expense | $4.11MM | $6.41MM |
| Income(Loss) | $-7.31MM | $-8.85MM |
| Taxes | $0.00MM | $0.00MM |
| Profit(Loss)* | $-7.31MM | $-8.85MM |
| Stockholders Equity | $4.27MM | $0.14MM |
| Assets | $4.45MM | $3.14MM |
| Operating Cash Flow | $-16.07MM | $-7.64MM |
| Capital expenditure | $0.00MM | $0.00MM |
| Investing Cash Flow | $4.96MM | $0.00MM |
| Financing Cash Flow | $12.79MM | $-0.49MM |
| Earnings Per Share** | $-0.21 | $-0.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.